Anti-CD38 immunotherapy treatment for multiple myeloma

Share :
Published: 22 Nov 2021
Views: 679
Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Prof Xavier Leleu speaks to ecancer about a discussion into anti-CD38 immunotherapy treatment that he participated in at the recent MyKE Myeloma 2021 meeting.

He explains that in recent years we have seen the success of the anti-CD38 immunotherapy agent daratumumab followed by another in isatuximab.

Prof Leleu discusses three different situations in which a sequence of daratumumab and isatuximab could be beneficial.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.